Boryung Holds Groundbreaking Ceremony for New Penicillin Production Facility... Production Capacity to Double

Boryung Co., Ltd. announced on November 12 that it held a groundbreaking ceremony for the expansion of its penicillin production facility at the "Boryung Ansan Campus," a pharmaceutical manufacturing site located in Ansan, Gyeonggi Province.

Participants are conducting a commemorative ceremony at the groundbreaking ceremony of Boryung Penicillin Co., Ltd.'s new production facility. Boryung

The ceremony was attended by National Assemblyman Park Haecheol (Ansan-si Byeong), Kim Myungho, Director of the Gyeongin Regional Office of Food and Drug Safety, Kim Woonhak, Head of Ansan City's Industrial Support Division, Lee Haengsin, Director of the Industrial Promotion Division at the Korea Health Industry Development Institute, Noh Yeonhong, Chairman of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association, and Ryu Hyungseon, Chairman of the Korea Pharmaceutical Traders Association, among others.

Starting with the groundbreaking ceremony, Boryung will officially begin the process of expanding its oral penicillin antibiotic production facilities. The total floor area of the production facility will increase by more than 50%, from 2,777 square meters (840 pyeong) to 4,364 square meters (1,320 pyeong), and annual production capacity is expected to more than double compared to the current level.

Through this expansion, the Ansan Campus plans to introduce equipment and quality management systems that meet global standards and begin product manufacturing. In particular, the facility will implement systems incorporating digital transformation elements such as packaging process automation and process innovation concepts, which are expected to reduce the burden and errors for workers, thereby improving both productivity and quality consistency.

Oral penicillin antibiotics were designated as national essential medicines by the Ministry of Food and Drug Safety in 2023 and have experienced supply chain instability since the COVID-19 pandemic. Boryung has been responsible for more than 60% of domestic contract supply volumes, serving as the largest manufacturing base in Korea. With this expansion, the company aims to establish a foundation for stable supply even during emergencies such as pandemics.

Noh Yeonhong, Chairman of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association, who attended the ceremony, stated, "With the groundbreaking of this production base, we have set a new milestone for establishing a stable supply chain and achieving self-sufficiency in domestic antibiotics. I hope this will be a new starting point that brightens the future of the industry and the public."

Ryu Hyungseon, Chairman of the Korea Pharmaceutical Traders Association, said, "In terms of safeguarding the nation's pharmaceutical sovereignty, this investment is more than just an industrial investment; it is a promise to fulfill our responsibility to sustain life. We will spare no effort to support the protection of essential medicine supply chains and to strengthen export competitiveness."

Kim Jungkyun, CEO of Boryung, commented, "This expansion of our production facility will be a crucial opportunity to enhance the production quality and increase the supply of penicillin antibiotics, which are national essential medicines. Based on this, Boryung will further strengthen the stable supply chain of essential medicines and fulfill its role as a company dedicated to protecting public health."

This content was produced with the assistance of AI translation services.